Searched for
GLENMARK LIFESCIENCES
Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
- Rs 12,000 crore magic pill race begins to shrink India's pot bellies. Which pharma stocks will win GLP-1 war?India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...
- Indian drugmakers flood market with cheaper versions of Novo's Ozempic, WegovyIndian drugmakers have launched affordable generic versions of popular diabetes and weight-loss drugs. This move significantly reduces trea...
- Glenmark set to join peers in 'Semaglutide' pushGlenmark Pharmaceuticals is set to launch affordable versions of the popular anti-diabetes and obesity drug semaglutide. This move escalate...
- Indian Pharmaceutical Alliance appoints Zydus Lifesciences MD Sharvil Patel as new presidentThe Indian Pharmaceutical Alliance (IPA) has appointed Sharvil Patel of Zydus Lifesciences as its new President, with Glenn Saldanha of Gle...
- IPA names Zydus Lifesciences MD Sharvil Patel as PresidentSharvil Patel is the new president of the Indian Pharmaceutical Alliance. He takes over from Samir Mehta. Glenn Saldanha becomes the vice p...
- Pharma raw material makers in race to tank up on CXO talentSome of these PE-owned platform companies include Advent International-led Cohance Lifesciences / Suven Pharma, PAG and CX Partners-funded ...
- Glenmark Pharma Q2 Results: Co posts loss on exceptional legal costsThe company posted a consolidated net loss, from continuing operations, of 2.01 billion rupees ($24.14 million) for the three months ended ...
- Sun Pharma, Lupin among 9 BSE Healthcare stocks that hit new 52-week highs on ThursdayThe healthcare sector's impressive performance in the stock market highlights these companies' commitment to innovation, research, and deli...
- Glenmark Pharma weighs selling stake in Glenmark Life in bid to reduce debtIt has been aiming to reduce its debt, including through the sale of some dermatology brands to Eris Lifesciences for Rs 3,400 crore in Jan...
- Eris Lifesciences acquires 9 dermatology brands from Dr Reddy's for Rs 275 crThe transaction will be financed through borrowings and will achieve financial closure in the next few days, the drug firm said. In a separ...
- Eris buys nine derma brands from Glenmark for Rs 340 croreThe nine brands have sales of Rs 87.30 crores for FY22, which represents valuation of 3.9x of the sales of these brands in FY22. The acquir...
- Eris Lifesciences to buy some dermatology brands from Glenmark PharmaThe deal for the portfolio that has an annual revenue base of 850 million rupees, will be financed through borrowings, and the transaction ...
- Eris Lifesciences to buy some dermatology brands from Glenmark PharmaThe deal, through Eris' dermatology focused unit, is for the purchase of nine brands, including Onabet, Halobate, Sorvate, and Demelan for ...
- Glenmark Q4 Results: Net dips 26% to Rs 173 crConsolidated revenues of the drug firm, however, rose to Rs 3,019 crore in the quarter under review as compared to Rs 2,860 crore in the ye...
- It's IPOs ahoy! 40-odd issues on the way to mop up Rs 80,000 croreIn 2020, 16 issues had mopped up Rs 26,628 crore, and a similar number of IPOs had collected Rs 12,687 crore in 2019, but 2018 was the best...
- Healthcare cos see a Covid lining, line up to raise record moneyAt least 12 drug makers and healthcare companies are planning IPOs in 2021 as the pandemic increases investor demand for the promising play...
- Faster USFDA nod won't boost margins, will lead to intense competition: AnalystsIndian drug makers may be receiving an increasing number of approvals from the USFDA for drug launches in the United States.
Load More
